Castle Biosciences, Inc. reported $357M of revenue over the trailing twelve months, +3.2% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $357M (to Q2 2026). Net income: −$19M, trailing twelve months to Q2 2026. Free cash flow: −$489K, trailing twelve months to Q2 2026. Operating margin: −9.4%, trailing twelve months to Q2 2026.

CSTLCastle Biosciences, Inc.

Healthcare

$33.72+47% 1Y

$33.72

$18.1552 weeks$43.04

CSTL as reported

Castle Biosciences, Inc. reported $357M of revenue over the trailing twelve months, +3.2% on the year before. 10 reported series are charted on this page, each one as filed.

$357M

Revenue, trailing twelve months · to Q2 2026 · +3.2% against the twelve months before

Net income: −$19M
Net income · +105% year on year · trailing twelve months to Q2 2026
Free cash flow: −$489K
Free cash flow · −101% year on year · trailing twelve months to Q2 2026
Operating margin: −9.4%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CSTL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$357M	+3.2%	Q2 2026
Net income	−$19M	+105%	Q2 2026
EPS	−$0.65	+86%	Q2 2026
Gross margin	77%	n/a	Q2 2026
Operating margin	−9.4%	n/a	Q2 2026
Net margin	−5.7%	n/a	Q2 2026
ROE	−3.7%	n/a	Q2 2026
ROA	−3.0%	n/a	Q2 2026
ROIC	−14%	n/a	Q2 2026
Free cash flow	−$489K	−101%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.